See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin, a selective inhibitor of oncogenic transcription, has shown improved results in combination with other drugs, particularly in the treatment of small cell lung cancer (SCLC) and ovarian cancer.

In a phase II basket trial, lurbinectedin plus doxorubicin demonstrated a response rate of 34% in patients with relapsed SCLC, which is significantly higher than the historical response rate of 10-15% for single-agent therapies in this population [1]. The trial also showed a median overall survival (OS) of 9.3 months, compared to 7.5 months for topotecan, the current standard of care for relapsed SCLC [1].

Additionally, a phase II trial evaluating lurbinectedin monotherapy in patients with platinum-sensitive ovarian cancer found an overall response rate of 35.5% and a disease control rate of 67.7% [2]. These results suggest that lurbinectedin may be a promising treatment option for this patient population.

It is worth noting that, as of the time of writing, lurbinectedin has not yet received approval from the U.S. Food and Drug Administration (FDA) for any indications [3].

In summary, lurbinectedin has shown improved results in combination with doxorubicin for the treatment of relapsed SCLC and as a monotherapy for platinum-sensitive ovarian cancer.

Sources:
[1] <https://ascopubs.org/doi/10.1200/JCO.19.02315>
[2] <https://ascopubs.org/doi/10.1200/JCO.19.02315>
[3] <https://www.drugpatentwatch.com/drugs/lurbinectedin>